Who are fatty acids, omega-3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Omega-3 Supplementation, Niacin plus laropiprant, nicotinic acid/laropiprant, Nicotinic acid (niacin), Niacin/ Laropiprant, omega-3-fatty acids (Omegaven).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fatty-acids-omega-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

fatty acids, omega-3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fatty acids, omega-3 (fatty acids, omega-3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent. Area: Cardiovascular.

marketed Lipid-modifying agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

fatty acids, omega-3 (fatty acids, omega-3) — National Heart, Lung, and Blood Institute (NHLBI). Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways to improve cardiovascular health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
fatty acids, omega-3 TARGET	fatty acids, omega-3	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Lipid-modifying agent
Omega-3 Supplementation	Omega-3 Supplementation	Università degli Studi di Brescia	marketed	Dietary supplement / Lipid-modifying agent	GPR120, GPR40, PPAR-γ, NF-κB signaling pathway
Niacin plus laropiprant	Niacin plus laropiprant	Institut Investigacio Sanitaria Pere Virgili	marketed	Lipid-modifying agent combination	DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways
nicotinic acid/laropiprant	nicotinic acid/laropiprant	Manchester University NHS Foundation Trust	marketed	Lipid-modifying agent / Antilipemic	GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways
Nicotinic acid (niacin)	Nicotinic acid (niacin)	Charite University, Berlin, Germany	marketed	Lipid-modifying agent; B vitamin	GPR109A (HM74A receptor)
Niacin/ Laropiprant	Niacin/ Laropiprant	Ludwig-Maximilians - University of Munich	marketed	Lipid-modifying agent; prostaglandin D2 receptor antagonist	DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant)
omega-3-fatty acids (Omegaven)	omega-3-fatty acids (Omegaven)	Li Shin Hospital	marketed	Lipid-modifying agent; anti-inflammatory

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent class)

National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fatty acids, omega-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/fatty-acids-omega-3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab